Background {#Sec1}
==========

Intravitreal injection (IVI) is one of the most common vitreoretinal procedures performed nowadays \[[@CR1]\]. Steroids, antibiotics, and antiviral drugs have been injected into the vitreous humor for many years, but the use of IVI has increased dramatically only recently after the introduction of anti-vascular endothelial growth factor (VEGF) therapy for neovascular age-related macular degeneration \[[@CR2]\]. Other indications for IVI of anti-VEGF include diabetic retinopathy, vascular occlusions, and cystoid macular edema \[[@CR3]\].

Patients may experience pain during IVI \[[@CR3]\], especially if multiple injections are required. The use of local anesthetics minimizes pain and avoids intraocular complications caused by pain-induced rapid, uncontrolled movements of the eye \[[@CR4]\]. Based on recent surveys, most ophthalmologists (65--90%) perform IVI using local anesthetic eye drops \[[@CR5]\]. Other techniques include the use of an anesthetic gel, peribulbar block, subconjunctival injection, and a pledget soaked in anesthetic \[[@CR3]\]. However, there is no consensus on the best anesthetic option \[[@CR6]\].

The choice of a single anesthetic technique for IVI requires careful evaluation of patient pain, ideally using an objective measure \[[@CR7]\]. However, patient pain is typically evaluated using one-dimensional tools such as numeric rating or visual analog scales \[[@CR8]\]. Such type of scales raises concerns of bias \[[@CR9]\].

To our knowledge, no systematic review has addressed patient pain during IVI under topical anesthesia. The aim of this systematic review was to evaluate the effectiveness of different local anesthetic techniques for IVI within the limitations of analog (visual or oral) pain scales.

Methods {#Sec2}
=======

This systematic review was written in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist \[[@CR10]\].

Protocol and registration {#Sec3}
-------------------------

The systematic review protocol was registered at the International Prospective Register of Systematic Reviews (PROSPERO) under number CRD42016037099.

Terminology {#Sec4}
-----------

For this systematic review, we compared different techniques of local anesthesia for IVI of antiangiogenic agents and steroids. Antiangiogenic agents included bevacizumab (Avastin^®^; Genentech/Roche, USA), ranibizumab (Lucentis^®^; Novartis, Switzerland), and aflibercept (Eylea^®^; Bayer HealthCare, Germany). Steroids included biodegradable dexamethasone implant of sustained release and triamcinolone. Local anesthetics included eye drop anesthetics (tetracaine, proparacaine, and cocaine), lidocaine gel, lidocaine pledget, subconjunctival anesthesia, and peribulbar block. Anesthetic and/or analgesic effect was evaluated using analogue (visual or oral) pain scales with grades ranging from 0 to 100 mm or from 0 to 10 cm.

Study design {#Sec5}
------------

The aim of this systematic review was to evaluate the effectiveness of different local anesthetic techniques for IVI of anti-VEFG agents or steroids within the limitations of analogue pain scales. Studies were selected in two steps. First, we classified patient-reported pain scores for each anesthetic technique covered by individual studies. Scales ranging from 0 to 10 cm or points were converted to a range from 0 to 100 mm. Other scales were not included in this review, due to heterogeneity. We classified pain by converting visual analog scale (VAS) scores (0--100 mm) into Jensen's classification levels \[[@CR8]\]: 0--4, no pain; 5--44, mild pain; 45--74, moderate pain; and 75--100, severe pain. Second, we considered that an intervention was clinically significant when pain score change was \>12 mm on a 100-mm scale. The relative value difference with clinical significance in patient perception comparing different treatments for pain varies from 9 to 15 mm in a 0 to 100 mm scale \[[@CR9], [@CR11]\], but higher values have been reported \[[@CR12]\]. For a conservative approach, we chose the average value of 12 mm, which we think reflects a clinically meaningful difference in pain perception.

Information sources {#Sec6}
-------------------

Studies to be considered for inclusion were identified by searching the following electronic bibliographic databases: Cochrane, LILACS, PubMed, Scopus, and Web of Science. An additional search of the gray literature was performed using Google Scholar. The end search date was February 19, 2016, across all databases. In addition, the reference lists of the selected articles were searched manually.

Appropriate truncation and word combinations were selected and adapted for each database search (Additional file [1](#MOESM1){ref-type="media"}: Table S1), with the aid of a health sciences librarian. All references were run through the reference manager software Mendeley^®^ (Elsevier), and duplicate hits were removed.

Study selection and eligibility criteria {#Sec7}
----------------------------------------

We reviewed studies whose objective was to compare the effect of different local anesthetic techniques for IVI of antiangiogenic agents and steroids using an analog (visual or oral) pain scale ranging from 0 to 100 (or 0--10).

There were two phases of review. In phase 1, we reviewed titles and abstracts and excluded the following: (1) studies conducted in infants (0--18 years); and (2) reviews, letters, conference abstracts, and editorials. In phase 2, we reviewed full-text articles and additionally excluded the following: (3) studies including sedation or general anesthetics for IVI; (4) studies including IVI of medications other than antiangiogenic agents or steroids; (5) non-randomized clinical trials; (6) studies using a pain scale other than an analogue (visual or oral) scale ranging from 0 to 100 or 0 to 10; (7) studies not evaluating pain at the moment of injection; and (8) studies not using mean as the measure of central tendency for pain score.

Two authors (HS, AT) independently reviewed all search results. In both phases, when disagreements emerged between the two reviewers, they tried to reach a consensus. When they were unable to reach a consensus, a third author (GLC) made the final decision. Articles that did not appear to meet the inclusion criteria were discarded. In phase 2, the same authors reviewed the full-text of the articles. The third author (GLC) read the abstracts of all the selected articles and made the final decision on inclusion; however, final selection was always based on the full text of the publication. The reference lists of selected studies were critically assessed by both HS and AT.

Data collection {#Sec8}
---------------

One author (HS) collected data from the selected studies. The following information was recorded: study background (authors, year, country, study design, and objective), population characteristics (number of patients, mean age), interventions (anesthetic techniques, type of medication, and pain grading), and outcomes (average pain score at the moment of injection and main conclusion). A second author (AT) crosschecked all the collected information and confirmed its accuracy. Again, any disagreement was resolved by discussion and mutual agreement among the three reviewers (HS, AT, LC).

Risk of bias in individual studies {#Sec9}
----------------------------------

The methodology of the selected studies was evaluated using the Cochrane Collaboration's risk of bias tool \[[@CR13]\]. The following characteristics were included in the assessment: sequence generation, allocation concealment, blinding of participants and personnel, potential threats to validity of performance, blinding of outcome assessment, and potential threats to validity of detection of bias \[[@CR13]\]. Two reviewers (HS, AT) independently assessed the quality of each included study. Disagreements between the reviewers were resolved through discussion.

Outcome measures {#Sec10}
----------------

The main outcome measure was the evaluation of the anesthetic/analgesic effect of different anesthetic techniques for IVI using analog (verbal or visual) pain scales.

Synthesis of results and risk of bias across studies {#Sec11}
----------------------------------------------------

If feasible, the possibility of meta-analysis and risk of bias across studies was considered.

Results {#Sec12}
=======

Study selection {#Sec13}
---------------

During the initial search (phase 1) and following duplicate removal, 374 different citations were identified across the five electronic databases. An additional search using Google Scholar found no additional relevant articles. After a comprehensive evaluation of the abstracts, 23 articles were deemed potentially relevant and were selected for phase 2. Of these 23 studies selected in the first evaluation, two studies using biodegradable dexamethasone implant included. However, those two studies were excluded, because they were not randomized. Others 13 were excluded (Additional file [2](#MOESM2){ref-type="media"}: Table S2). Thus, only eight studies were retained for the final selection. A flowchart of the process of literature search and selection is shown in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Flow Diagram of literature search and selection criteria.(adapted from PRISMA)

Study characteristics {#Sec14}
---------------------

A summary of the study characteristics is shown in Table [1](#Tab1){ref-type="table"}. The selected studies were conducted in Brazil \[[@CR1], [@CR6]\], Canada \[[@CR11]\], Turkey \[[@CR14]\], UK \[[@CR15]\], and USA \[[@CR2], [@CR5], [@CR16]\] from 2008 to 2015. The total number of patients for all studies was 847. The injected medications were ranibizumab, bevacizumab, and triamcinolone.Table 1Summary of characteristics of the included studiesStudy backgroundParticipantsInterventionsOutcomesReferences (country)ObjectiveCases, *n*Mean age, yearsGroups according to anesthetic techniquePain gradingDrugAverage pain scoreMain conclusionBlaha et al. \[[@CR16]\] (USA)To compare pain scores during injection versus total procedure for four anesthetic techniques9680G1: 0.5% topical proparacainePain was graded on a 0 to 10 scaleRNZ, BVZG1: 3.0No statistical difference in pain scores for the four anesthetic techniques. Topical drops provided excellent anesthesia in a quick, comfortable, and safe manner for IVIG2: 0.5% topical tetracaineG2: 2.8G3: topical proparacaine + 4% lidocaine pledgetG3: 2.3G4: topical proparacaine + SC injection of 2% lidocaineG4: 3.1\
*p* = 0.28Yau et al. \[[@CR11]\] (Canada)To compare the anesthetic effectiveness of three topical agents used for IVIs93Group 1: 83.6G1: 0.5% tetracaine hydrochloride drops + 4% lidocaine pledget for 10Patients graded pain on a 100-mm VAS, or by saying a number from 0 to 100RNZG1: 19 (12--26)No clinical (statistical) difference in patient pain between the three topical agents tested. The addition of a 4% lidocaine pledget for 10" offered no clinical advantage in pain relief compared to 0.5% tetracaine or 4% cocaine drops aloneGroup 2: 79.5G2: 0.5% tetracaine hydrochloride dropsG2: 21 (13--29)Group 3: 82.1G3: 4% cocaine + epinephrine 1/100.000 dropsG3: 21 (16--27)Örnek et al. \[[@CR14]\] (Turkey)To compare the efficacy of topical 0.75% levobupivacaine and 0.5% proparacaine9663.97G1: 0.75% levobupivacaine dropsPatients graded pain on a 100-mm VASRNZ, TACG1: 44.77 ± 16.420.5% topical proparacaine was more effective than 0.75% topical levobupivacaine in preventing pain during IVIG2: 0.5% proparacaine dropsG2: 34.18 ± 14.83\
*p* = 0.003Shiroma et al. \[[@CR1]\] (Brazil)To investigate the safety and anesthetic efficacy of five concentrations of lidocaine gel26070.1G1: 2% lidocaine gelPatients graded pain on a 0 to 10 scaleRNZG1: 2.63 ± 1.68Lidocaine gel at concentrations from 2% to 12% induced similar anesthetic effect for IVIG2: 3.5% lidocaine gelG2: 2.08 ± 1.35G3: 5% lidocaine gelG3: 2.00 ± 1.65G4: 8% lidocaine gelG4: 1.93 ± 1.40G5: 12% lidocaine gelG5: 1.83 ± 1.35\
*p* = 0.077Andrade et al. \[[@CR6]\] (Brazil)To compare the anesthetic effectiveness of topical proparacaine drops, SC lidocaine, and 2% lidocaine gel9266.4G1: proparacainePatients graded pain on a 0 to 10 scaleBVZG1: 3.2 ± 1.7SC injection of lidocaine was most effective in preventing pain during IVI compared to proparacaine or 2% lidocaine gelG2: proparacaine + SC injection of 2% lidocaineG2: 1.0 ± 1.0G3: 2% lidocaine gelG3: 1.0 ± 1.1Kumar et al. \[[@CR15]\] (UK)To compare patient comfort during IVI after SC anesthesia or topical eye drops30G1: 72G1: 0.5% proximetacainePatients graded pain on a 0 to 10 scaleTACG1: 0.87 ± 0.83There was no significant difference in pain scores or overall satisfaction scores between the two groupsG2: 74G2: SC injection of 2% lidocaineG2: 0.93 ± 0.96\
*p* = 0.84Davis et al. \[[@CR2]\] (USA)To compare the anesthetic effect among topical proparacaine drops, 4% lidocaine solution, and 3.5% lidocaine gel12080.18G1: 0.5% topical proparacainePatients graded pain on a 0 to 10 scaleBVZ, RNZ, TACG1: 1.78 ± 1.44There was no significant difference in pain scores or overall satisfaction scores between the different groupsG2: topical proparacaine + 4% lidocaine pledgetG2: 1.75 ± 1.46G3: 3.5% lidocaine gelG3: 1.48 ± 1.58\
*p* = 0.38Rifkin and Schaal \[[@CR5]\] (USA)To determine factors associated with patient comfort during in-office IVI6065G1: 0.5% TetraViscPatients graded pain on a 0 to 10 scaleBVZ, RNZ, TACG1: 3.39 ± 2.26The tetracaine group reported the lowest painG2: proparacaineG2: 3.17 ± 2.18G3: tetracaineG3: 3.05 ± 2.01\
*p* \< 0.01*G* group, *IVI* intravitreal injection, *SC*, subconjunctival, *RNZ*, ranibizumab, *BVZ* bevacizumab, *AFL* aflibercept, *TAC* triamcinolone acetonide

Risk of bias within studies {#Sec15}
---------------------------

Selection biases were evaluated through random sequence generation and allocation concealment. We judged only three (37.5%) of the eight studies to be at low risk of bias based on random sequence generation and allocation concealment; the other studies were considered to be at unclear risk of bias because of unclear randomization process, thus providing moderate level of evidence to this review. We present other potential sources of bias as percentages in Fig. [2](#Fig2){ref-type="fig"} and per study in Fig. [3](#Fig3){ref-type="fig"}.Fig. 2Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies (n = 8) Fig. 3Risk of bias summary: review authors' judgments about each risk of bias for each included study

Characteristics of included studies {#Sec16}
-----------------------------------

The characteristics of the eight studies evaluating the effect of different local anesthetic techniques for IVI of antiangiogenic agents and steroids using analog (visual or oral) pain scales are summarized in Table [1](#Tab1){ref-type="table"}.

Anesthetic methods {#Sec17}
------------------

Different anesthetics methods were recorded and compared among the included studies. The described techniques included eye drops with proparacaine \[[@CR2], [@CR5], [@CR6], [@CR14]--[@CR16]\] and tetracaine \[[@CR5], [@CR11], [@CR16]\], 4% lidocaine pledgets \[[@CR11]\], 4% cocaine + epinephrine 1/100,000 drops \[[@CR11]\], subconjunctival injection of 2% lidocaine \[[@CR6], [@CR15]\], lidocaine gel at 2, 3.5, 5, 8 and 12% \[[@CR1], [@CR2], [@CR6]\], and 0.75% levobupivacaine \[[@CR14]\].

Classification of studies according to pain {#Sec18}
-------------------------------------------

We classified pain by converting (VAS) scores (0--100 mm) into Jensen's classification levels \[[@CR8]\]: 0--4, no pain; 5--44, mild pain; 45--74, moderate pain; and 75--100, severe pain. Only six studies evaluated pain at the moment of IVI \[[@CR1], [@CR2], [@CR5], [@CR6], [@CR11], [@CR14]\]. On the other hand, Blaha et al. \[[@CR16]\] and Kumar et al. \[[@CR15]\] considered a combined score calculated by adding the discomfort for anesthesia and the IVI.

Patient pain was mild in all studies regardless of anesthetic technique or definition of pain scores (single or combined) (Table [2](#Tab2){ref-type="table"}). A meta-analysis was not possible due to high study heterogeneity.Table 2Pain in the included studies according to Jensen's classification \[[@CR8]\]References (country)Groups according to anesthetic methodDifference in painMean pain score related to discomfort of anesthesiaMean pain score during injectionMean global painJensen's classificationBlaha et al. \[[@CR16]\] (USA)G1: 0.5% topical proparacaineNSG1: 14G1: 30G1: 44G1: MIG2: 0.5% topical tetracaineG2: 7G2: 28G2: 35G2: MIG3: topical proparacaine + 4% lidocaine pledgetG3: 16G3: 23G3: 39G3: MIG4: topical proparacaine + SC injection of 2% lidocaineG4: 10\
*p* = 0.17 (NS)G4: 31\
*p* = 0.28 (NS)G4: 41\
*p* = 0.65 (NS)G4: MIYau et al. \[[@CR11]\] (Canada)G1: 0.5% tetracaine hydrochloride drops + 4% lidocaine pledget for 10NSNAG1: 19NAG1: MIG2: 0.5% tetracaine hydrochloride dropsG2: 21G2: MIG3: 4% cocaine + epinephrine 1/100.000 dropsG3: 21G3: MIÖrnek et al. \[[@CR14]\] (Turkey)G1: 0.75% levobupivacaine dropsStatistically different, but not clinically significantNAG1: 44.77NAG1: MIG2: 0.5% proparacaine dropsG2: 34.18\
*p* = 0.003G2: MIShiroma et al. \[[@CR1]\] (Brazil)G1: 2% lidocaine gelNSG1: 0G1: 26.3 ± 16.8G1: 26.3G1: MIG2: 3.5% lidocaine gelG2: 0G2: 20.8 ± 13.5G2: 20.8G2: MIG3: 5% lidocaine gelG3: 0G3: 20.0 ± 16.5G3: 20.0G3: MIG4: 8% lidocaine gelG4: 0G4: 19.3 ± 14.0G4: 19.3G4: MIG5: 12% lidocaine gelG5: 0G5: 18.3 ± 13.5G5: 18.3G5: MIAndrade et al. \[[@CR6]\] (Brazil)G1: proparacaineSC injection of 2% lidocaine was most effective, with clinical significance (\>12 mm)NAG1: 32 ± 17NAG1: MIG2: proparacaine + SC injection of 2% lidocaineG2: 10 ± 10G2: MIG3: 2% lidocaine gelG3: 10 ± 11\
*p* = 0.02G3: MIKumar et al. \[[@CR15]\] (UK)G1: 0.5% proximetacaineNSG1: 6.0 ± 0.63G1: 8.7 ± 0.83G1: 14.7G1: MIG2: SC injection of 2% lidocaineG2: 6.0 ± 0.96G2: 9.3 ± 0.96\
*p* = 0.84G2: 15.3G2: MIDavis et al. \[[@CR2]\] (USA)GA: 0.5% topical proparacaineNSNAG1: 17.8 ± 14.4NAG1: MIGB: topical proparacaine + 4% lidocaine pledgetG2: 17.5 ± 14.6G2: MIGC: 3.5% lidocaine gelG3: 14.8 ± 15.8\
*p* = 0.38G3: MIRifkin and Schaal \[[@CR5]\] (USA)G1: 0.5% TetraViscStatistically different, but not clinically significantNAG1: 33.9 ± 22.6NAG1: MIG2: proparacaineG2: 31.7 ± 21.8G2: MIG3: tetracaineG3: 30.5 ± 20.1\
*p* \< 0.01G3: MI*G* group, *MI* mild, *S* significant, *NS* not significant, *NA* not available

Clinically meaningful difference in pain scores {#Sec19}
-----------------------------------------------

Pain scores reflecting clinically significant anesthetic techniques for IVI are shown in Table [2](#Tab2){ref-type="table"}. Three studies \[[@CR5], [@CR6], [@CR14]\] showed a statistically significant difference in pain scores between different anesthetic techniques. However, only one study \[[@CR6]\] presented a clinically significant pain score change of at least 12 mm in a 100 mm scale.

Andrade et al. \[[@CR6]\] compared the anesthetic effectiveness of topical proparacaine drops alone, proparacaine + subconjunctival injection of 2% lidocaine, and 2% lidocaine gel in 92 patients. A subconjunctival injection of 2% lidocaine was most effective in preventing pain compared with the two other groups. Difference in pain score between subconjuctival injection (10 mm) or lidocaine gel (10 mm) versus proparacaine (32 mm) was 22 mm. These differences were considered clinically meaningful.

Discussion {#Sec20}
==========

Our systematic review of the literature revealed mild pain in studies about IVI of antiangiogenic agents and steroids, regardless of anesthetic technique. With moderate level of evidence, no single anesthetic technique could be defined as the best option for IVI.

Comparison of anesthetic techniques requires the use of appropriate pain assessment tools \[[@CR17]\]. Pain VAS and numerical rating scales (NRS) are considered reliable to evaluate the efficacy of anesthetic or analgesic treatments \[[@CR8]\]. Some trials also use four-point verbal categorical pain scales (VRS) to assess discomfort, although VAS and NRS are considered superior to VRS \[[@CR9]\]. VAS and NRS have similar sensitivity, and the choice between them is subjective. To provide a meaningful interpretation of pain scale scores, we converted pain scores into Jensen's levels of pain \[[@CR8]\]. All included studies presented mild discomfort during IVI, regardless of anesthetic technique. In this setting, even an effective treatment would show only a small change in pain intensity, and a comparison among anesthetic techniques would probably exhibit low sensitivity \[[@CR17]\]. Of the eight included studies, three studies \[[@CR5], [@CR6], [@CR14]\] showed a statistically significant difference in VAS or NRS pain scores between different anesthetic techniques. However, only one study \[[@CR6]\] found a clinically significant pain score change of at least 12 mm in a 100 mm VAS or NRS scale. In that study, Andrade et al. \[[@CR6]\] concluded that a subconjunctival injection of 2% lidocaine was most effective in preventing pain compared to lidocaine gel or proparacaine drops. However, Andrade et al. \[[@CR6]\] did not describe the level of discomfort during IVI under subconjunctival anesthesia. Moreover, Kumar et al. \[[@CR15]\] failed to observe similar benefits of the subconjunctival approach. The penetration and duration of gel is an important point in topical anesthesia. Lidocaine is absorbed extensively following mucosal intramuscular, rectal, transdermal, and inhalation pathways \[[@CR18]\], studies showed the anesthesia with lidocaine 3.5% gel was achieved within 5 min of application in 92% of the subjects \[[@CR19]\].

Rodrigues et al. demonstrated that smaller gauge needles 30-G induced less pain than 26-G. In other study published by van Asten et al. comparing ultrathin 33-G needles or 30-G needle concluded that 33-G needle did not result in lower IVI pain (*p* = 0.758), but tended to cause less vitreal reflux (*p* = 0.054) and may limit scleral damage \[[@CR20], [@CR21]\].

Rifkin and Schaal published a study evaluating patients' during intravitreal injection, under topical anesthesia, and observed factors that could influence pain: improved vision from previous injection, female sex, and age \>65 years and number of injections, where pain scores decreased with each consecutive injection. \[[@CR5]\] However, in a study published by Moisseiev et al., did not confirm these correlation. They also evaluated the injection site (quadrant), number of injections, presence of diabetes mellitus, and lens status. On analysis of injection location by quadrants, such a trend existed toward less pain in the inferonasal quadrant \[[@CR22]\].

A meta-analysis was not considered feasible due to high study heterogeneity. This lack of homogeneity was related to the many different anesthetic techniques compared in each study. In addition, some authors combined the discomfort associated with the anesthetic procedure itself to the pain score, while others did not.

Surveys of retina specialists in different countries demonstrated a predominance of topical anesthetic eye drops for IVI \[[@CR5], [@CR23]\]. Indeed, in all studies included in this systematic review, proparacaine or tetracaine drops were used; eye drops were either combined with other types of anesthetics to relieve the discomfort caused by dilating drops or povidone iodine drops, or as a single anesthetic choice.

Although eye drops were effective in all selected studies, we could not define a single local anesthetic technique as the gold standard for IVI. Individual preferences, either from the ophthalmologist or the patient, should guide the choice of topical anesthesia. Perhaps, in patients with high sensitivity to pain, a subconjunctival injection of 2% lidocaine could be an option. Considering only pain scores, the low level of discomfort associated to the procedure makes comparing anesthetic techniques a challenge due to low sensitivity. Future studies should focus on side effects of drugs or patient rejection of a specific technique rather than preference.

One of the limitations of this systematic review is the heterogeneity of the included studies, with no synthesis of individual results. Ranking of pain scores according to Jensen's classification is reliable even in the absence of a meta-analysis, but neither it derives from a statistical tool nor it generates a single median score for each technique. Nonetheless, only three of the included studies were judged to be at low risk of bias based on random sequence generation.

The aim of this review was to evaluate the effectiveness of different local anesthetic techniques for IVI. We considered the pain only at the moment of injection. Chemical keratitis could cause discomfort, even hours after the injection, caused by anesthetics or mydriatic drops, lidocaine gel or PVPI. It usually solved before the first postoperative day.

In conclusion, patient pain was mild in all studies regardless of anesthetic technique. With moderate level of evidence, no single anesthetic technique could be defined as the best option for IVI. Although complete pain relief was not attained, a subconjunctival injection of 2% lidocaine could be an option for highly sensitive patients. Mild pain suggests future studies should focus on side effects or rejection of a specific technique rather than preference.
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